{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001437","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.739236+00:00","generated_at":"2026-05-24T23:02:53.629442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%","bullets":["Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).","Commercial Channel revenue up 25% in Q4 ($10.9M) and 17% for full year ($42.1M).","Net loss from continuing ops: Q4 ($2.5M), ($0.17)/share; FY ($8.8M), ($0.60)/share.","FY 2025 guidance: Commercial Channel $47-49.5M (+12-18%), OEM Channel $64-68.5M (-12-18%).","Sale of Parcus Medical completed Mar 7; $5.6M in stock repurchased in Q4, $15M plan completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001437","json":"https://secwatch.observer/filing/0001171843-25-001437.json","markdown":"https://secwatch.observer/filing/0001171843-25-001437.md","text":"https://secwatch.observer/filing/0001171843-25-001437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001437/0001171843-25-001437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001437/f8k_031225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:02:53.629442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}